logo
logo2

Privacy Policy



Any data collected by HRA Pharma from the users through this website are solely used to generate statistics on the frequency of website use and how the site is used. Personal data related to patients (for the purpose of ordering our pharmaceutical products through our distributor) are not collected through this website.

The following data are collected through the use of this website:

  • The domain and server (host) from which the user accessed the website on the Internet
  • In cases of failure, the address of the website from which the user accessed our site (www.hra-pharma.com)
  • The date, time and length of visits to the website, and details of which pages were accessed
  • The user’s internet protocol (IP) address
  • The operating system of the user’s computer and details of the user’s web browser

With respect to collecting anonymous traffic data, we may use third parties to collect such data on our behalf. To disable or limit the use of cookies, please refer to the options provided by your Internet browser. If you do so, however, some pages or features (such as customised products/services or user preferences) on this Web site may not work properly.

However, with the express consent of the user, some personal data such as forename, surname, e-mail address, and place of work may be collected by HRA Pharma in order to permit HRA Pharma to meet its requirements for providing information and/or services by mail or e-mail. HRA Pharma will not share, sell or rent your personal data collected through this website and takes all reasonable action to maintain the protection of such data.

In compliance with the “Informatique et Libertés” law (computers and freedom of expression) dated January 6th 1978, the user has the right to access, modify, rectify and delete all data concerning themselves (article 34 of this same law). To exercise this right, please contact dataprivacy@HRA-PHARMA.COM. You can find all details related to the law “Informatique et Libertés” on the web site for CNIL.



Indication and Important Safety Information

Metopirone® is a diagnostic drug for testing hypothalamic-pituitary ACTH function.

Metopirone is contraindicated in patients with adrenal cortical insufficiency, or hypersensitivity to Metopirone or to any of its excipients. Ability of adrenals to respond to exogenous ACTH should be demonstrated before Metopirone is employed as a test. In the presence of hypo- or hyperthyroidism, response to the Metopirone test may be subnormal.

Since Metopirone® may cause dizziness and sedation, patients should exercise caution when driving or operating machinery.

The following adverse reactions have been observed after use of Metopirone®: Hypotension, nausea, vomiting, abdominal discomfort or pain, headache, dizziness, sedation, allergic rash, and rarely, decreased white blood cell count or bone marrow depression.

See Instructions for Use and full prescribing information in the use of this product. To report SUSPECTED ADVERSE REACTIONS, contact Direct Success Pharmacy, Inc. at 1-855-M-Pirone (1-855-674-7663) or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.

HRA Pharma, 15, rue Béranger, 75003 Paris, FRANCE
Tel: +33 (0) 1 40 33 11 30 / Fax: +33 (0) 1 40 33 12 31
© 2018 HRA Pharma - Privacy Policy | Disclaimer
Last updated: February 2018; MET-WEB-0218-US